Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Outcomes of Surgical and Chemotherapeutic Treatments of Goblet Cell Carcinoid Tumors of the Appendix.

Tsang ES, McConnell YJ, Schaeffer DF, Lee L, Yin Y, Zerhouni S, Schaff K, Speers C, Kennecke HF.

Ann Surg Oncol. 2018 Jun 18. doi: 10.1245/s10434-018-6560-0. [Epub ahead of print]

PMID:
29916007
2.

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Lui A, Mulder K, Brezden-Masley C, Vickers M, Monzon J, Kennecke H, Goel R, Vos L, Ghosh S, Marginean H, Fields A, Maroun J, Spratlin J.

Invest New Drugs. 2018 May 4. doi: 10.1007/s10637-018-0599-4. [Epub ahead of print]

PMID:
29725881
3.

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, Alcindor T, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L.

Clin Colorectal Cancer. 2018 Mar 8. pii: S1533-0028(17)30462-0. doi: 10.1016/j.clcc.2018.03.001. [Epub ahead of print]

PMID:
29653857
4.

Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.

Loree JM, Sha A, Soleimani M, Kennecke HF, Ho MY, Cheung WY, Mulder KE, Abadi S, Spratlin JL, Gill S.

Clin Colorectal Cancer. 2018 Jun;17(2):156-163. doi: 10.1016/j.clcc.2018.01.010. Epub 2018 Feb 7.

PMID:
29486916
5.

Prognostic Factors for Locoregional Recurrence in Neuroendocrine Tumors of the Rectum.

Tsang ES, McConnell YJ, Schaeffer DF, Yin Y, Speers CH, Kennecke HF.

Dis Colon Rectum. 2018 Feb;61(2):187-192. doi: 10.1097/DCR.0000000000000996.

PMID:
29337773
6.

Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.

Loree JM, Tan SK, Lafond LM, Speers CH, Kennecke HF, Cheung WY.

Clin Colorectal Cancer. 2018 Mar;17(1):65-72. doi: 10.1016/j.clcc.2017.10.011. Epub 2017 Oct 23.

PMID:
29153430
7.

Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.

Wong HL, Yang KC, Shen Y, Zhao EY, Loree JM, Kennecke HF, Kalloger SE, Karasinska JM, Lim HJ, Mungall AJ, Feng X, Davies JM, Schrader K, Zhou C, Karsan A, Jones SJM, Laskin J, Marra MA, Schaeffer DF, Gorski SM, Renouf DJ.

Cold Spring Harb Mol Case Stud. 2018 Feb 1;4(1). pii: a002329. doi: 10.1101/mcs.a002329. Print 2018 Feb.

8.

Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration.

Segelov E, Chan D, Lawrence B, Pavlakis N, Kennecke HF, Jackson C, Law C, Singh S.

J Glob Oncol. 2016 Oct 12;3(4):380-388. doi: 10.1200/JGO.2016.006916. eCollection 2017 Aug.

9.

Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study.

Abdel-Rahman O, Kumar A, Kennecke HF, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2018 Mar;17(1):e21-e28. doi: 10.1016/j.clcc.2017.06.003. Epub 2017 Jun 23.

PMID:
28709877
10.

Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2.

Weiswald LB, Hasan MR, Wong JCT, Pasiliao CC, Rahman M, Ren J, Yin Y, Gusscott S, Vacher S, Weng AP, Kennecke HF, Bièche I, Schaeffer DF, Yapp DT, Tai IT.

Mol Cancer Ther. 2017 Oct;16(10):2292-2303. doi: 10.1158/1535-7163.MCT-16-0666. Epub 2017 Jun 29.

PMID:
28663269
11.

The utility of abbreviated patient-reported outcomes for predicting survival in early stage colorectal cancer.

Hsu T, Speers CH, Kennecke HF, Cheung WY.

Cancer. 2017 May 15;123(10):1839-1847. doi: 10.1002/cncr.30511. Epub 2017 Jan 12.

12.

Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.

Tehfe M, Dowden S, Kennecke H, El-Maraghi R, Lesperance B, Couture F, Letourneau R, Liu H, Romano A.

Adv Ther. 2017 Jan;34(1):277-279. doi: 10.1007/s12325-016-0442-2. No abstract available.

13.

Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer.

Loree JM, Kennecke HF, Lee-Ying RM, Goodwin RA, Powell ED, Tang PA, Price Hiller JA, Vickers MM, Cheung WY.

Am J Clin Oncol. 2018 Jul;41(7):643-648. doi: 10.1097/COC.0000000000000342.

PMID:
27819876
14.

Patterns of practice with third-line anti-EGFR antibody for metastatic colorectal cancer.

Ho MY, Renouf DJ, Cheung WY, Lim HJ, Speers CH, Zhou C, Kennecke HF.

Curr Oncol. 2016 Oct;23(5):329-333. Epub 2016 Oct 25.

15.

Impact of Travel Distance and Urban-Rural Status on the Multidisciplinary Management of Rectal Cancer.

Loree JM, Javaheri KR, Lefresne SV, Speers CH, Ruan JY, Chang JT, Brown CJ, Kennecke HF, Olson RA, Cheung WY.

J Rural Health. 2017 Sep;33(4):393-401. doi: 10.1111/jrh.12219. Epub 2016 Oct 7.

PMID:
27717002
16.

Population-Based Patterns and Factors Associated With Underuse of Palliative Systemic Therapy in Elderly Patients With Metastatic Colon Cancer.

Chan M, Hugh-Yeun K, Gresham G, Speers CH, Kennecke HF, Cheung WY.

Clin Colorectal Cancer. 2017 Jun;16(2):147-153. doi: 10.1016/j.clcc.2016.08.004. Epub 2016 Aug 30.

PMID:
27670894
17.

αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis.

Voduc KD, Nielsen TO, Perou CM, Harrell JC, Fan C, Kennecke H, Minn AJ, Cryns VL, Cheang MCU.

NPJ Breast Cancer. 2015 Oct 21;1. pii: 15014. doi: 10.1038/npjbcancer.2015.14.

18.

A Comparison of Survival by Site of Metastatic Resection in Metastatic Colorectal Cancer.

Lee-Ying R, Bernard B, Gresham G, Chen L, Speers C, Kennecke HF, Lim HJ, Cheung WY, Renouf DJ.

Clin Colorectal Cancer. 2017 Jun;16(2):e23-e28. doi: 10.1016/j.clcc.2016.07.018. Epub 2016 Aug 9.

PMID:
27637559
19.

Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy.

Loree JM, Kennecke HF, Renouf DJ, Lim HJ, Vickers MM, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2016 Dec;15(4):352-359.e1. doi: 10.1016/j.clcc.2016.04.003. Epub 2016 May 7.

PMID:
27265355
20.

Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus.

Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R, Mete O, Pasieka J, Rivera J, Wong R, Segelov E, Rayson D.

Cancer Treat Rev. 2016 Jun;47:32-45. doi: 10.1016/j.ctrv.2016.05.003. Epub 2016 May 17. Review.

PMID:
27236421
21.

nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.

Tehfe M, Dowden S, Kennecke H, El-Maraghi R, Lesperance B, Couture F, Letourneau R, Liu H, Romano A.

Adv Ther. 2016 May;33(5):747-59. doi: 10.1007/s12325-016-0327-4. Epub 2016 Apr 16. Erratum in: Adv Ther. 2016 Nov 24;:.

22.

Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).

Barry GS, Cheang MC, Chang HL, Kennecke HF.

Oncotarget. 2016 Apr 5;7(14):18953-64. doi: 10.18632/oncotarget.8006.

23.

Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases.

Loree JM, Hiruki T, Kennecke HF.

Case Rep Oncol. 2016 Jan 30;9(1):76-82. doi: 10.1159/000443985. eCollection 2016 Jan-Apr.

24.

Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.

Wilson S, Speers C, Tyldesley S, Chia S, Kennecke H, Ellard S, Lohrisch C.

Clin Breast Cancer. 2016 Aug;16(4):284-90. doi: 10.1016/j.clbc.2015.11.002. Epub 2015 Nov 17.

PMID:
26705158
25.

Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.

Ko JJ, Kennecke HF, Lim HJ, Renouf DJ, Gill S, Woods R, Speers C, Cheung WY.

Clin Colorectal Cancer. 2016 Jun;15(2):179-85. doi: 10.1016/j.clcc.2015.09.002. Epub 2015 Sep 30.

PMID:
26520019
26.

Simplified 2-tier histologic grading system accurately predicts outcomes in goblet cell carcinoid of the appendix.

Lee LH, McConnell YJ, Tsang E, Zerhouni S, Speers C, Kennecke H, Schaeffer DF.

Hum Pathol. 2015 Dec;46(12):1881-9. doi: 10.1016/j.humpath.2015.08.005. Epub 2015 Aug 22.

PMID:
26433702
27.

Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes.

Vergidis J, Gresham G, Lim HJ, Renouf DJ, Kennecke HF, Ruan JY, Chang JT, Cheung WY.

Clin Colorectal Cancer. 2016 Mar;15(1):16-23. doi: 10.1016/j.clcc.2015.07.002. Epub 2015 Jul 26.

PMID:
26281943
28.

Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

Dascalu B, Kennecke HF, Lim HJ, Renouf DJ, Ruan JY, Chang JT, Cheung WY.

Support Care Cancer. 2016 Feb;24(2):799-805. doi: 10.1007/s00520-015-2846-y. Epub 2015 Jul 17.

PMID:
26184500
29.

Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.

Ho MY, Kennecke HF, Renouf DJ, Cheung WY, Lim HJ, Gill S.

Am J Clin Oncol. 2017 Dec;40(6):552-554. doi: 10.1097/COC.0000000000000205.

PMID:
26165420
30.

Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.

Kumar A, Peixoto RD, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2015 Dec;14(4):262-8.e1. doi: 10.1016/j.clcc.2015.05.010. Epub 2015 Jun 6.

PMID:
26123496
31.

Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014.

Ahmed S, Bathe O, Berry S, Buie D, Davies J, Doll C, Dowden S, Gill S, Gordon V, Hebbard P, Jones E, Kennecke H, Koski S, Krahn M, Le D, Lim H, Lund C, Luo Y, Mcffadden A, Mcghie J, Mulder K, Park J, Rashidi F, Sami A, Tan KT, Wong R.

Curr Oncol. 2015 Apr;22(2):e113-23. doi: 10.3747/co.22.2362.

32.

Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer.

Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF.

Cancer Med. 2015 Aug;4(8):1171-7. doi: 10.1002/cam4.459. Epub 2015 Apr 18.

33.

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).

Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD.

Cancer. 2015 Jul 1;121(13):2193-7. doi: 10.1002/cncr.29363. Epub 2015 Mar 30.

34.
35.

Time to adjuvant chemotherapy and survival outcomes among patients with stage 2 to 3 rectal cancer treated with preoperative chemoradiation.

Gresham G, Cheung WY, Speers C, Woods R, Kennecke H.

Clin Colorectal Cancer. 2015 Mar;14(1):41-5. doi: 10.1016/j.clcc.2014.11.004. Epub 2014 Nov 20.

PMID:
25548075
36.

Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.

Peixoto RD, Kumar A, Speers C, Renouf D, Kennecke HF, Lim HJ, Cheung WY, Melosky B, Gill S.

Clin Colorectal Cancer. 2015 Mar;14(1):25-30. doi: 10.1016/j.clcc.2014.10.002. Epub 2014 Nov 4.

PMID:
25465343
37.

Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.

Singh S, Dey C, Kennecke H, Kocha W, Maroun J, Metrakos P, Mukhtar T, Pasieka J, Rayson D, Rowsell C, Sideris L, Wong R, Law C.

Ann Surg Oncol. 2015 Aug;22(8):2685-99. doi: 10.1245/s10434-014-4145-0. Epub 2014 Nov 4.

PMID:
25366583
38.

Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.

Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, Speers C, Cheung WY.

Cancer. 2015 Feb 15;121(4):527-34. doi: 10.1002/cncr.29072. Epub 2014 Oct 20.

39.

Factors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer.

Chan A, Woods R, Kennecke H, Gill S.

Curr Oncol. 2014 Aug;21(4):181-6. doi: 10.3747/co.21.1963.

40.

Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs.

Peixoto RD, Noonan KL, Pavlovich P, Kennecke HF, Lim HJ.

J Gastrointest Oncol. 2014 Aug;5(4):247-52. doi: 10.3978/j.issn.2078-6891.2014.019.

41.

Effect of M1a and M1b category in metastatic colorectal cancer.

Kennecke H, Yu J, Gill S, Cheung WY, Blanke CD, Speers C, Woods R.

Oncologist. 2014 Jul;19(7):720-6. doi: 10.1634/theoncologist.2013-0442. Epub 2014 Jun 4.

42.

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.

Thind G, Johal B, Follwell M, Kennecke HF.

Radiat Oncol. 2014 May 29;9:124. doi: 10.1186/1748-717X-9-124.

43.

Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patients.

Gresham G, Renouf DJ, Chan M, Kennecke HF, Lim HJ, Brown C, Cheung WY.

Ann Surg Oncol. 2014 Nov;21(12):3917-23. doi: 10.1245/s10434-014-3797-0. Epub 2014 May 24.

PMID:
24859937
44.

Acute gout episodes during treatment with capecitabine: a case report.

Peixoto RD, Cossetti R, Lim H, Cheung WY, Kennecke H.

Gastrointest Cancer Res. 2014 Mar;7(2):59-60. No abstract available.

45.

Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer.

Kennecke H, Chen L, Blanke CD, Cheung WY, Schaff K, Speers C.

Curr Oncol. 2013 Dec;20(6):326-32. doi: 10.3747/co.20.1600.

46.

Surgical management of node-positive prostate cancer: perspectives from breast oncology.

Kennecke HF, Keyes M.

Eur Urol. 2014 Aug;66(2):202-3. doi: 10.1016/j.eururo.2013.09.007. Epub 2013 Sep 13. No abstract available.

PMID:
24094573
47.

Screening intervention to identify eligible patients and improve accrual to phase II-IV oncology clinical trials.

Chen L, Grant J, Cheung WY, Kennecke HF.

J Oncol Pract. 2013 Jul;9(4):e174-81. doi: 10.1200/JOP.2012.000763. Epub 2013 Mar 5.

48.

Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer.

Yang BB, Wu CY, Chen E, Infante JR, Chen A, Gao B, Smith B, Litten J, Kennecke H.

Clin Pharmacol Drug Dev. 2013 Jul;2(3):205-12. doi: 10.1002/cpdd.35. Epub 2013 May 15.

PMID:
27121781
49.

Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence.

Wong JC, Hasan MR, Rahman M, Yu AC, Chan SK, Schaeffer DF, Kennecke HF, Lim HJ, Owen D, Tai IT.

Int J Cancer. 2013 Oct 1;133(7):1567-77. doi: 10.1002/ijc.28180. Epub 2013 Apr 30.

50.

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M, McCaffery I, Loh E, Gansert JL, Kaufman PA.

Lancet Oncol. 2013 Mar;14(3):228-35. doi: 10.1016/S1470-2045(13)70026-3. Epub 2013 Feb 13.

PMID:
23414585

Supplemental Content

Loading ...
Support Center